Evoke Pharma Pre-Tax Profit Margin 2012-2025 | EVOK
Evoke Pharma pre-tax profit margin from 2012 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Evoke Pharma Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2025-09-30 | $0.01B | $-0.01B | -35.71% |
| 2025-06-30 | $0.01B | $-0.01B | -38.46% |
| 2025-03-31 | $0.01B | $0.00B | -33.33% |
| 2024-12-31 | $0.01B | $-0.01B | -45.45% |
| 2024-09-30 | $0.01B | $-0.01B | -60.00% |
| 2024-06-30 | $0.01B | $-0.01B | -77.78% |
| 2024-03-31 | $0.01B | $-0.01B | -114.29% |
| 2023-12-31 | $0.01B | $-0.01B | -133.33% |
| 2023-09-30 | $0.01B | $-0.01B | -160.00% |
| 2023-06-30 | $0.00B | $-0.01B | -200.00% |
| 2023-03-31 | $0.00B | $-0.01B | -266.67% |
| 2022-12-31 | $0.00B | $-0.01B | -400.00% |
| 2022-09-30 | $0.00B | $-0.01B | -800.00% |
| 2022-06-30 | $0.00B | $-0.01B | -800.00% |
| 2022-03-31 | $0.00B | $-0.01B | -800.00% |
| 2021-12-31 | $0.00B | $-0.01B | -900.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |